Sage Therapeutics, Inc. (NASDAQ:SAGE) Expected to Earn Q1 2025 Earnings of ($1.62) Per Share

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Sage Therapeutics in a report released on Friday, April 26th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will post earnings of ($1.62) per share for the quarter. HC Wainwright has a “Neutral” rating and a $25.00 price objective on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.49) per share. HC Wainwright also issued estimates for Sage Therapeutics’ Q2 2025 earnings at ($1.59) EPS, Q3 2025 earnings at ($1.13) EPS and Q4 2025 earnings at ($1.15) EPS.

A number of other research analysts have also recently issued reports on the stock. JPMorgan Chase & Co. lifted their target price on shares of Sage Therapeutics from $24.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, March 26th. Canaccord Genuity Group cut their target price on shares of Sage Therapeutics from $21.00 to $17.00 and set a “hold” rating for the company in a research note on Friday. Oppenheimer cut their target price on shares of Sage Therapeutics from $25.00 to $17.00 and set a “market perform” rating for the company in a research note on Thursday, April 18th. StockNews.com upgraded shares of Sage Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a research note on Thursday. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $37.72.

Sage Therapeutics Trading Up 0.8 %

NASDAQ SAGE opened at $13.69 on Monday. The stock’s 50 day moving average is $18.56 and its two-hundred day moving average is $20.65. The company has a market capitalization of $823.86 million, a price-to-earnings ratio of -1.63 and a beta of 0.86. Sage Therapeutics has a 1-year low of $10.92 and a 1-year high of $59.99.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.17). The company had revenue of $7.90 million for the quarter, compared to analyst estimates of $5.26 million. Sage Therapeutics had a negative net margin of 552.52% and a negative return on equity of 54.17%. The firm’s revenue for the quarter was up 139.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.46) earnings per share.

Hedge Funds Weigh In On Sage Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. RTW Investments LP acquired a new position in Sage Therapeutics in the 3rd quarter worth $105,976,000. Jacobs Levy Equity Management Inc. acquired a new position in Sage Therapeutics in the 3rd quarter worth $8,052,000. Rafferty Asset Management LLC lifted its position in Sage Therapeutics by 197.1% during the 3rd quarter. Rafferty Asset Management LLC now owns 411,904 shares of the biopharmaceutical company’s stock worth $8,477,000 after buying an additional 273,257 shares in the last quarter. Hudson Bay Capital Management LP lifted its position in Sage Therapeutics by 1,733.3% during the 3rd quarter. Hudson Bay Capital Management LP now owns 275,000 shares of the biopharmaceutical company’s stock worth $5,660,000 after buying an additional 260,000 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in Sage Therapeutics by 3.3% during the 3rd quarter. Wellington Management Group LLP now owns 6,572,260 shares of the biopharmaceutical company’s stock worth $135,257,000 after buying an additional 208,630 shares in the last quarter. Institutional investors and hedge funds own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.